Antisense pharma internationalizes management board

B3C newswire, 05/11/2012

The biopharmaceutical company Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native–born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies–including Hofmann La–Roche and ICI Pharmaceuticals–and has successfully guided several medicines from their clinical development to their commercialization. Dr. Calais steps in for interim Chief Executive Officer Dr. Hubert Heinrichs, who led the business on an interim basis in addition to his primary duties as Chief Medical Officer since July of last year.

Print Article Summary Cat 2 CME Report